Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

NCT00877110 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

71

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma
Bone Marrow, Sympathetic Nervous System

Interventions

DRUG: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8

Sponsor

Memorial Sloan Kettering Cancer Center